Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Day One Biopharmaceuticals
Fierce Pharma
Servier rounds out rare cancer offerings with $2.5B Day One buy
Servier has unveiled a deal to acquire commercial-stage Day One Biopharmaceuticals and its med Ojemda for $21.50 per share in cash.
Fraiser Kansteiner
Mar 6, 2026 10:14am
Day One pens $285M deal for Mersana
Nov 13, 2025 10:15am
Sanofi vaccine vet vaults to GSK—Chutes & Ladders
Jun 13, 2025 8:30am
Pfizer replaces retiring CSO with cancer chief—Chutes & Ladders
Nov 22, 2024 8:30am
Day One doles out $55M for MabCare’s solid tumor ADC
Jun 18, 2024 10:55am
MHRA CEO Raine to depart in Autumn —Chutes & Ladders
Mar 1, 2024 9:30am
